Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke. (VANS)
Primary Purpose
Ischemic Stroke, Thrombotic Stroke, Autonomic Dysfunction
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
trans-cutaneous auricular sensory stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Ischemic Stroke
Eligibility Criteria
Inclusion Criteria:
- Undergoing mechanical thrombectomy for acute ischaemic stroke requiring general or sedation.
- Established hypertensive and/or hypertensive on admission for mechanical thrombectomy [systolic BP >140mmHg; diastolic BP >80mmHg]
Exclusion Criteria:
- Current participation in a clinical trial of a treatment with a similar biological mechanism.
- Previous enrolment into VANS trial.
- Anatomical or other contraindication to trans-cutaneous auricular sensory stimulation
- Pregnancy.
Sites / Locations
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Stimulation
Electrode attachment only.
Arm Description
Electrodes attached bliaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current.
Electrodes attached bliaterally to tragus nerve region of outer ear, with device switched off [blinded to operator].
Outcomes
Primary Outcome Measures
Blood pressure variability
Coefficient of variation of systolic blood pressure
Secondary Outcome Measures
Systolic and diastolic blood pressure variability in the first 24h after mechanical thrombectomy
Systolic and diastolic blood pressure standard deviation, average real variability, successive variation and residual standard deviation
Heart rate variability
Time and frequency domain measures of autonomic cardiac modulation
NIH Stroke Scale (NIHSS)
FDA-approved primary outcome measure for stroke in early phase II trials.
Organ dysfunction
Clinical need for intravenous pharmacological support for blood pressure [pressors or intravenous antihypertensive medication]; arrythmias; myocardial injury [high sensitivity troponin]; hospital-acquired infection.
Full Information
NCT ID
NCT05417009
First Posted
June 8, 2022
Last Updated
August 3, 2023
Sponsor
Queen Mary University of London
1. Study Identification
Unique Protocol Identification Number
NCT05417009
Brief Title
Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.
Acronym
VANS
Official Title
Vagal Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke Requiring Mechanical Thrombectomy.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
April 26, 2023 (Actual)
Primary Completion Date
July 21, 2023 (Actual)
Study Completion Date
July 21, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Queen Mary University of London
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Autonomic modulation by transcutaneous vagal nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: a phase IIa, sham controlled randomised trial.
Detailed Description
Loss of autonomic variability is strongly associated with adverse outcomes after ischaemic stroke. Removing blood clots from the brain by mechanical thrombectomy has revolutionised the management of stroke, but more than 50% of patients do not regain functional independence.(PMID:26898852) Blood pressure (BP) control is important, since low and high BP (BP variability) are strongly associated with poor patient outcomes after thrombectomy. (PMIDs:32961389;31964286) Autonomic dysfunction causes labile blood pressure. Intact autonomic function is required to control blood pressure and potentially improve recovery after stroke. Impairment of baroreflex autonomic function, due to reduced vagal activity is associated with extreme BP variability, leading to further brain injury and cardiovascular complications.(PMID:30371208) Reduced baroreflex control is related to poor patient outcomes after stroke, independent of absolute blood pressure.(PMID:19834010) Reversing baroreflex and vagal dysfunction is, therefore, widely held to have the potential to improve cardiovascular control and patient outcome in this context.(PMID:19834010)
Non-invasive peripheral neuromodulation restores autonomic control. Vagal nerve stimulation improves autonomic control and reverses baroreflex dysfunction (PMIDs:28949064) but this has previously required surgically implanted devices which are expensive and impractical in the context of acute stroke. Afferent Electronic have achieved the same effect as these implantable devices by non-invasive transcutaneous autonomic neuromodulation (TAN). We have used this simple, safe, hand-held, low-cost device to increase vagal activity and baroreflex sensitivity through non-invasive, painless stimulation of nerves located in the outer ear to control blood pressure.
Baroreflex sensitivity can be increased at the bedside by TAN for 30 minutes following acute trauma. If this can be replicated in thrombectomy patients, it will aid recovery and rehabilitation through five complementary mechanisms where it has been clinically demonstrated that increasing vagal nerve activity:
Restore baroreflex sensitivity;
Increase blood flow to ischaemic brain tissue through vagal activation.(PMID:27357059)
Dampen cerebral/systemic inflammation.(PMID:26723020);
Reduce atrial fibrillation and myocardial injury,(PMIDs:5744003,22739118) which are common after stroke, and independently predict cognitive decline and cardiovascular mortality
Allows immediate commencement of vagal nerve stimulation, which has recently been shown to enhance upper-limb rehabilitation.(PMID:33894832) Our proof-of-concept data shows daily TAN reduces BP and BP variability lasting several months even in drug-resistant hypertensive patients. In this proof-of-concept randomised sham-controlled trial, we will examine whether early TAN on presentation for mechanical thrombectomy improves autonomic function in patients with acute ischaemic stroke by reducing blood pressure lability.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Stroke, Thrombotic Stroke, Autonomic Dysfunction, Autonomic Imbalance
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
RCT
Masking
ParticipantOutcomes Assessor
Masking Description
Sham settings for neuromodulation device.
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stimulation
Arm Type
Active Comparator
Arm Description
Electrodes attached bliaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current.
Arm Title
Electrode attachment only.
Arm Type
Sham Comparator
Arm Description
Electrodes attached bliaterally to tragus nerve region of outer ear, with device switched off [blinded to operator].
Intervention Type
Device
Intervention Name(s)
trans-cutaneous auricular sensory stimulation
Intervention Description
Transcutaneous auricular sensory stimulation
Primary Outcome Measure Information:
Title
Blood pressure variability
Description
Coefficient of variation of systolic blood pressure
Time Frame
0-24h after mechanical thrombectomy
Secondary Outcome Measure Information:
Title
Systolic and diastolic blood pressure variability in the first 24h after mechanical thrombectomy
Description
Systolic and diastolic blood pressure standard deviation, average real variability, successive variation and residual standard deviation
Time Frame
0-24h after mechanical thrombectomy
Title
Heart rate variability
Description
Time and frequency domain measures of autonomic cardiac modulation
Time Frame
0-24h after mechanical thrombectomy
Title
NIH Stroke Scale (NIHSS)
Description
FDA-approved primary outcome measure for stroke in early phase II trials.
Time Frame
recorded before, at 24h and 7 days after mechanical thrombectomy
Title
Organ dysfunction
Description
Clinical need for intravenous pharmacological support for blood pressure [pressors or intravenous antihypertensive medication]; arrythmias; myocardial injury [high sensitivity troponin]; hospital-acquired infection.
Time Frame
First seven days after mechanical thrombectomy.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Undergoing mechanical thrombectomy for acute ischaemic stroke requiring general or sedation.
Established hypertensive and/or hypertensive on admission for mechanical thrombectomy [systolic BP >140mmHg; diastolic BP >80mmHg]
Exclusion Criteria:
Current participation in a clinical trial of a treatment with a similar biological mechanism.
Previous enrolment into VANS trial.
Anatomical or other contraindication to trans-cutaneous auricular sensory stimulation
Pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gareth L Ackland, PhD FRCA
Organizational Affiliation
William Harvey Research Institute, Queen Mary University of London
Official's Role
Principal Investigator
Facility Information:
Facility Name
William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square
City
London
ZIP/Postal Code
EC1M 6BQ
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Researchers who provide a methodologically sound proposal approved by an independent review committee intermediary using deidentified data.
IPD Sharing Time Frame
No end date.
IPD Sharing Access Criteria
To achieve aims in approved proposal.
Learn more about this trial
Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.
We'll reach out to this number within 24 hrs